Neurogene (NASDAQ:NGNE - Get Free Report) released its earnings results on Monday. The company reported ($0.99) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.05, Zacks reports. The firm had revenue of $0.93 million during the quarter.
Neurogene Stock Down 5.3 %
NASDAQ:NGNE traded down $0.81 during midday trading on Friday, hitting $14.52. The stock had a trading volume of 98,611 shares, compared to its average volume of 210,041. The stock has a 50-day moving average of $16.88 and a 200 day moving average of $28.76. The company has a market capitalization of $215.69 million, a price-to-earnings ratio of -3.40 and a beta of 1.01. Neurogene has a one year low of $13.47 and a one year high of $74.49.
Wall Street Analyst Weigh In
A number of analysts have recently commented on the company. William Blair reissued an "outperform" rating on shares of Neurogene in a research note on Tuesday. HC Wainwright decreased their price target on Neurogene from $55.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $59.80.
Check Out Our Latest Analysis on NGNE
Insider Transactions at Neurogene
In related news, CFO Christine Mikail Cvijic sold 4,501 shares of the firm's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $16.94, for a total transaction of $76,246.94. Following the completion of the transaction, the chief financial officer now owns 72,343 shares of the company's stock, valued at $1,225,490.42. This trade represents a 5.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 9.92% of the company's stock.
About Neurogene
(
Get Free Report)
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Read More
Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
